会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES
    • WO2007071598A1
    • 2007-06-28
    • PCT/EP2006/069625
    • 2006-12-13
    • F. HOFFMANN-LA ROCHE AGBUETTELMANN, BerndHAN, BoKNUST, HennerKOBLET, AndreasTHOMAS, Andrew
    • BUETTELMANN, BerndHAN, BoKNUST, HennerKOBLET, AndreasTHOMAS, Andrew
    • C07D413/04C07D413/14A61K31/4245A61K31/4439A61P25/28
    • C07D413/04C07D413/14
    • The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula (I) wherein R 1 is hydrogen, halogen, aryl, heterocyclyl, heteroaryl, cyano, lower alkyl, -(CH 2 ) n -cycloalkyl, -(CH 2 ) n -N(R) 2 , -(CH 2 ) n -O-lower alkyl or -(CH 2 ) n -OH; n is 0,1 or 2 R is hydrogen or lower alkyl; R 2 is cycloalkyl, aryl, heteroaryl or heterocyclyl, which are optionally substituted by one or more substituents, selected from the group consisting of halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen, lower alkyl substituted by halogen, C(O)O-lower alkyl, lower alkylsulfonyl, -NR a R b , -C(O)-NR a R b , -C(O)-heterocyclyl, benzyloxy, heterocyclyl optionally substituted by hydroxy, halogen or lower alkyl, or is heteroaryl optionally substituted by lower alkyl; R a and R b are independently hydrogen, lower alkylsulfonyl, -C(O)H, -(CH 2 ) n -N(R) 2 , -(CH 2 ) n -O-lower alkyl, -(CH 2 ) n -S-lower alkyl, -(CH 2 ) n -S(O) 2 -lower alkyl, heteroarylsulfonyl, lower alkyl, -(CH2)n-heterocyclyl, optionally substituted by lower alkyl, or is -(CH 2 ) n -cycloalkyl, -(CH 2 ) n -heteroaryl, -(CH 2 ) n -OH, -(CO)-R', wherein R' is lower alkyl, cycloalkyl or heteroaryl; R 3 is aryl or heteroaryl, which are optionally substituted by halogen or lower alkyl substituted by halogen; as well as pharmaceutically acceptable acid addition salts thereof. It has been found that this class of compounds show high affinity and selectivity for GABA α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    • 本发明涉及式(I)的异恶唑-4-基 - 恶二唑衍生物,其中R 1是氢,卤素,芳基,杂环基,杂芳基,氰基,低级烷基, - (CH
    • 3. 发明申请
    • ARYL-ISOXAZOL-4-YL-IMIDAZO[1, 5-A]PYRIDINE DERIVATIVES
    • ARYL-ISOXAZOL-4-YL-IMIDAZO [1,5-A]吡啶衍生物
    • WO2007074089A1
    • 2007-07-05
    • PCT/EP2006/069792
    • 2006-12-18
    • F. HOFFMANN-LA ROCHE AGBUETTELMANN, BerndDONG, JiaqiangHAN, BoKNUST, HennerTHOMAS, Andrew
    • BUETTELMANN, BerndDONG, JiaqiangHAN, BoKNUST, HennerTHOMAS, Andrew
    • C07D471/04A61K31/4188A61K31/437A61P25/28
    • C07D471/04
    • The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives of formula (I) wherein: R 1 is hydrogen, halogen, hydroxy, lower alkyl, benzyloxy or -O-(CH 2 )-(CO)-5 or 6 membered heteroaryl optionally substituted by aryl and lower alkyl; R 2 is hydrogen, lower alkyl, or -(CO)-R a ; R 3 is hydrogen, halogen, cyano, lower alkyl, or -(CO)-R a ; R a is hydroxy, lower alkoxy, NR'R'', wherein R' and R'' are each independently hydrogen, cycloalkyl, 5 or 6-membered heterocycloalkyl or lower alkyl optionally substituted by cycloalkyl, cyano, 5 or 6-membered heterocycloalkyl or 5 or 6-membered heteroaryl; as well as pharmaceutically acceptable acid addition salts thereof. It has been found that this class of compounds show high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    • 本发明涉及式(I)的芳基 - 异恶唑-4-基 - 咪唑并[1,5-a]吡啶衍生物,其中:R 1是氢,卤素,羟基,低级烷基, 任选被芳基和低级烷基取代的苄氧基或-O-(CH 2)2 - (CO)-5或6元杂芳基; R 2是氢,低级烷基或 - (CO)-R a; R 3是氢,卤素,氰基,低级烷基或 - (CO)-R a)。 R“是羟基,低级烷氧基,NR'R”,其中R'和R“各自独立地为氢,环烷基,5或6元杂环烷基或任选被环烷基取代的低级烷基,氰基 ,5或6元杂环烷基或5或6元杂芳基; 以及其药学上可接受的酸加成盐。 已经发现,这类化合物显示出对GABA A a5受体结合位点的高亲和力和选择性,并且可用作认知增强剂或用于治疗认知障碍如阿尔茨海默氏病。
    • 4. 发明申请
    • ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS
    • ARYL-ISOXAZOL-4-YL-IMIDAZO [1,2-A]吡啶可用于通过GABA受体治疗阿尔茨海默病
    • WO2007082806A1
    • 2007-07-26
    • PCT/EP2007/050137
    • 2007-01-08
    • F. HOFFMANN-LA ROCHE AGBUETTELMANN, BerndHAN, BoKNUST, HennerTHOMAS, Andrew
    • BUETTELMANN, BerndHAN, BoKNUST, HennerTHOMAS, Andrew
    • C07D471/04A61K31/437A61P25/28
    • C07D471/04
    • The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives of formula (I): wherein R 1 is hydrogen, halogen, hydroxy, lower alkyl, benzyloxy or -O-(CH 2 )-(CO)-5 or 6 membered heteroaryl optionally substituted by aryl or by lower alkyl; R 2 is hydrogen, halogen, lower alkyl, lower alkynyl, amino, -NHC(O)-R a or -(CO)-R a ; R 3 is hydrogen, halogen, cyano, lower alkyl, lower alkynyl, amino, -NHC(O)-R a , -(CO)-R a , -5 or 6-membered heterocycloalkyl in 1-position, optionally substituted 10 by =O or is a -5 or 6-membered heteroaryl in 1-position; R 4 is hydrogen or -5 or 6-membered heteroaryl; R 5 is lower alkyl or cycloalkyl; R a is lower alkoxy or NR'R'', wherein R' and R'' are each independently hydrogen, lower alkyl optionally substituted by hydroxy, lower alkynyl, -(CH 2 ) n -cycloalkyl, 15 -(CH 2 ) n -5 or 6-membered heterocycloalkyl or -(CH 2 ) n -5 or 6-membered heteroaryl; n is 0 to 3; as well as pharmaceutically acceptable acid addition salts thereof. It has been found that this class of compounds show high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    • 本发明涉及式(I)的芳基 - 异恶唑-4-基 - 咪唑并[1,2-a]吡啶衍生物:其中R 1是氢,卤素,羟基,低级烷基, 任选被芳基或低级烷基取代的苄氧基或-O-(CH 2 - ) - (CO)-5或6元杂芳基; R 2是氢,卤素,低级烷基,低级炔基,氨基,-NHC(O)-R a或 - (CO)-R a, SUP>; R 3是氢,卤素,氰基,低级烷基,低级炔基,氨基,-NHC(O)-R a, - (CO)-R a 1-位的-5或6-元杂环烷基,任选地被10取代或被1位置的5或6元杂芳基取代; R 4是氢或-5或6元杂芳基; R 5是低级烷基或环烷基; R“是低级烷氧基或NR'R”,其中R'和R“各自独立地为氢,任选被羟基取代的低级烷基,低级炔基, - (CH 2) 15 - (CH 2)n - 或 - 或 - 6元杂环烷基或 - (CH 2) -5或6元杂芳基; n为0〜3; 以及其药学上可接受的酸加成盐。 已经发现,这类化合物显示出对GABA A a5受体结合位点的高亲和力和选择性,并且可用作认知增强剂或用于治疗认知障碍如阿尔茨海默氏病。
    • 5. 发明申请
    • ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES
    • WO2007074078A3
    • 2007-07-05
    • PCT/EP2006/069722
    • 2006-12-14
    • F. HOFFMANN-LA ROCHE AGBUETTELMANN, BerndHAN, BoKNUST, HennerTHOMAS, Andrew
    • BUETTELMANN, BerndHAN, BoKNUST, HennerTHOMAS, Andrew
    • C07D413/04A61K31/42A61K31/4178
    • The present invention is concerned with aryl-isoxazol-4-yl-imidazole derivatives of formula (I), wherein R 1 to R 3 are each independently hydrogen or halogen; R 4 is hydrogen, lower alkyl, cycloalkyl, -(CH 2 ) n -O-lower alkyl or lower alkyl substituted by hydroxy; R 5 is -(CH 2 ) m -aryl or -(CH 2 ) m -heteroaryl which are optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkyl substituted by halogen, -C(O)-lower alkyl, -C(O)-O-lower alkyl, -NH-C(O)-O-lower alkyl or -C(O)-NH-R', wherein R' is lower alkynyl or lower alkyl substituted by halogen, or is -(CH 2 ) n -cycloalkyl, -(CH 2 ) n -heterocyclyl, -(CH 2 ) n -heteroaryl or -(CH 2 ) n -aryl, optionally substituted by halogen; R 6 is hydrogen, -C(O)H, -(CH 2 ) n -O-lower alkyl, -C(O)O-lower alkyl, lower alkyl substituted by hydroxy or halogen, or is cycloalkyl, aryl, or is -(CH 2 ) n -O-CH 2 -aryl, optionally substituted by halogen or lower alkyl, or is -(CH 2 ) n -O-CH 2 -heteroaryl, optionally substituted by halogen, lower alkyl or lower alkyl substituted by halogen, or is -(CH 2 ) n -NH-(CH 2 ) o -heterocyclyl; n is 0, 1, 2 or 3 m is 0 or 1; o is 1, 2 or 3; as well as with pharmaceutically acceptable acid addition salts thereof. It has been found that this class of compounds show high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    • 10. 发明申请
    • ISOXAZOLO-PYRIDAZINE DERIVATIVES
    • ISOXAZOLO-PYRIDAZINE衍生物
    • WO2009071477A1
    • 2009-06-11
    • PCT/EP2008/066226
    • 2008-11-26
    • F. HOFFMANN-LA ROCHE AGBUETTELMANN, BerndJAKOB-ROETNE, RolandKNUST, HennerTHOMAS, Andrew
    • BUETTELMANN, BerndJAKOB-ROETNE, RolandKNUST, HennerTHOMAS, Andrew
    • C07D413/12C07D413/14C07D487/04A61K31/501A61K31/5025A61P25/28
    • C07D413/12C07D413/14C07D487/04
    • The invention relates to compounds of formula (I) wherein X is O or NH; R 1 is phenyl, pyridinyl, or pyrimidinyl each optionally substituted with one, two or three halo, R 2 is C 1-4 alkyl, H or C 1-4 haloalkyl; R 3 , R 4 , and R 5 each are independently H, optionally substituted Ci-7alkyl, optionally substituted Cι.7alkoxy, CN, halo, NO2, -C(O)-R a -NR b R c , optionally substituted 3- to 7-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, -C(0)-NR d R e , or R 3 together with the neighboring pyridazine-nitrogen form a 5-membered optionally substituted annelated aromatic ring with two additional ring nitrogen atoms, or to a pharmaceutically acceptable salt thereof, having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as cognitive enhancers or for the treatment of cognitive disorders like Alzheimer's disease.
    • 本发明涉及其中X为O或NH的式(I)化合物; R 1是苯基,吡啶基或嘧啶基,每个任选被一个,两个或三个卤素取代,R 2是C 1-4烷基,H或C 1-4卤代烷基; R 3,R 4和R 5各自独立地为H,任选取代的C 1-7烷基,任选取代的C 1-7烷氧基,CN,卤素,NO 2,-C(O)-R a -NR b R c,任选取代的3-至7-元杂环基, 任选取代的5-或6-元杂芳基,-C(O)-NR d R e或R 3与相邻的哒嗪 - 氮形成具有两个另外的环氮原子的5元任选取代的环状芳环,或与药学上可接受的盐 具有对GABA A a5受体结合位点的亲和性和选择性,它们的制备,含有它们的药物组合物及其作为药物的用途。 本发明的活性化合物可用作认知增强剂或治疗认知障碍如阿尔茨海默氏病。